摘要
目的研究头孢哌酮/舒巴坦治疗呼吸机相关性肺炎的临床疗效。方法 136例呼吸机相关性肺炎患者随机分为头孢哌酮/舒巴坦治疗组和头孢他啶对照组,疗程均为14d,治疗前后行痰培养。结果治疗组与对照组临床疗效、细菌清除率分别为91.18%、94.44%和70.59%、74.29%,两组临床疗效与细菌清除率差异均有统计学意义(P<0.05)。结论头孢哌酮/舒巴坦治疗呼吸机相关性肺炎效果好,可作为治疗呼吸机相关性肺炎患者的经验用药。
OBJECTIVE To evaluate the clinical efficacy of cefperazone/sulbactam for ventilator-associated pneumonia（VAP）. METHODS Totally 136 cases of VAP patients were randomized into cefoperazone/sulbactam group and ceftazidime group, and sputum culture was underwent for each case before and after treatment. RESULTS The total efficacy rates and bacterial eradication rates in cefoperazone/sulbactam group and ceftazidime group were 91.18% and 94.44% and 70.59% and 74.29%, respectively, and the differences between the two groups were statistically significant. CONCLUSIONS It suggests that cefoperazone/sulbactam is a more effective drug for VAP.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2010年第11期1592-1593,共2页
Chinese Journal of Nosocomiology
